Camphor toxicity

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Background

  • Common topical agent for pain relief, wart removal, osteoarthritis, cold sores, cough suppression, nasal decongestion
  • FDA limits over the counter preparations to 11%[1]
  • Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes
  • CNS stimulant when ingested

Clinical Features

Differential Diagnosis

Evaluation

Management

Disposition

See Also

References

  1. United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983
  2. American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128